Search

everythinglearnresearchcommunity

for

Search:↓

User shared 100-day progress on Minoxidil (5%, 10%, 12.5%), finasteride 1 mg, Biotin, and Vitamin D3. They documented improvements in hair growth.

The user is using topical minoxidil twice daily for hair regrowth and is hesitant to use finasteride due to concerns about hormonal effects. The conversation includes mixed opinions on the effectiveness of the treatment and suggestions to use a DHT blocker for better results.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

A 23-year-old experiencing diffuse hair thinning has chosen a treatment stack including topical finasteride, a blend of rosemary, peppermint, and pumpkin seed oils, procyanidine B2 spray, ketoconazole shampoo, and scalp massages. They avoid minoxidil due to family history of side effects and oral finasteride due to high estrogen levels.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

The post is about whether there is any additional benefit to using alfatradiol or other estrogen treatments for hair loss if someone is already using finasteride, dutasteride, or an androgen receptor inhibitor like RU58841, pyrithione zinc, or fluridil.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

The conversation discusses dissatisfaction with current hair loss treatments that mainly focus on DHT blockers like finasteride and dutasteride. Alternative treatments mentioned include RU58841, pyrilutamide, minoxidil, rosemary oil, and future possibilities like hair cloning.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The conversation is about a person using oral minoxidil, biotin multivitamins, dutasteride lotion, a hair growth serum with redensyl, capixyl, and procapil, ketoconazole with zinc shampoo, and monthly PRP treatments with a derma roller for hair growth. Someone encouraged them to continue with their regimen.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The user has been using minoxidil, finasteride, dermastamping, and Nizoral for hair loss with initial success but is considering adding PRP due to slowed progress. Concerns about PRP include potential ineffectiveness and whether it could harm existing hair growth or interfere with current treatments.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A user successfully regrew hair using finasteride, minoxidil, ketoconazole shampoo, biotin supplements, and rosemary mint oil, despite initial side effects. They highlighted the need for commitment, a healthy lifestyle, and being a "hyper responder" to treatments.

Hair loss discussion includes Latanoprost as potential treatment. Mild improvement observed with its use.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The user is considering using Minoxidil and Tretinoin to manage hair loss while waiting for Breezula/PP405, as they cannot tolerate dutasteride or finasteride. They hope these treatments will help retain hair despite ongoing loss.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, latanoprost, tretinoin, dutasteride, and cetirizine, with concerns about effectiveness, cost, and potential side effects. Users express skepticism about the product's price and the combination of multiple compounds.

Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.

A user experimenting with an extreme hair loss treatment stack of Dutasteride, RU58841, 15 mg oral minoxidil, and microneedling, which sparked a debate among other users about the safety of this approach.

The user experienced decreased libido with saw palmetto and is now considering topical anti-androgens like RU58841, pyrilutamide, and topical dutasteride for hair loss. Minoxidil is also mentioned as a potential addition, but the user is cautious about side effects and availability of treatments.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.